Evidence map›Paper›PMID 40166466›Full record

ArticleFrontiers in pharmacology2025

Onvansertib exhibits anti-proliferative and anti-invasive effects in endometrial cancer.

Nikita Sinha, Xiaochang Shen, Jennifer Haag, Shuning Chen, Haomeng Zhang, Catherine John, Wenchuan Sun, Michael Emanuele, Chunxiao Zhou, Victoria Bae-Jump

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nikita Sinha *Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Xiaochang Shen *Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Jennifer HaagDivision of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Shuning ChenDivision of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Haomeng ZhangDivision of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Catherine JohnDivision of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Wenchuan SunDivision of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Michael EmanueleDepartment of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Chunxiao ZhouDivision of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Victoria Bae-JumpDivision of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polo-like kinase 1 (Plk1) is widely recognized as an oncogene that promotes cell proliferation by regulating cell division, DNA damage response, and genome stability and has been shown to be overexpressed in many cancers, including endometrial cancer. Targeting Plk1 by onvansertib has been shown to have anti-tumor activity in pre-clinical models of multiple cancers and is currently being evaluated in phase 1 and 2 clinical trials in cancer patients. In this study, we evaluated the potential anti-tumorigenic effects of onvansertib in endometrial cancer cells and the LKB1

Indexed as

apoptosiscell proliferationendometrial cancerinvasiononvansertibpolo-like kinase 1

Identifiers

PMID40166466
PMCPMC11955691

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.